Invivyd (IVVD) Liabilities and Shareholders Equity (2020 - 2025)
Invivyd (IVVD) posted Liabilities and Shareholders Equity of $276.9 million for Q4 2025, up 98.97% on a QoQ basis from $139.2 million in Q3 2025, and up 113.78% year-over-year from $129.5 million in Q4 2024.
Invivyd (IVVD) Liabilities and Shareholders Equity (2020 - 2025) Analysis & Trends
Invivyd's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $276.9 million for Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 113.78% year-over-year to $276.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $608.9 million (down 11.01% YoY) and the FY2025 annual result came in at $276.9 million, up 113.78% from the prior year.
- Liabilities and Shareholders Equity was $276.9 million for Q4 2025 at Invivyd, up from $139.2 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $686.3 million in Q3 2021 and bottomed at $89.1 million in Q2 2025.
- A 5-year average of $316.7 million and a median of $276.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 428.27% — and 2025, when it tumbled 51.85%.
- Invivyd's Liabilities and Shareholders Equity stood at $620.1 million in 2021, then tumbled by 38.21% to $383.2 million in 2022, then slumped by 40.19% to $229.2 million in 2023, then tumbled by 43.49% to $129.5 million in 2024, then surged by 113.78% to $276.9 million in 2025.
- Business Quant data shows IVVD's Liabilities and Shareholders Equity at $276.9 million in Q4 2025, $139.2 million in Q3 2025, and $89.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 78.88 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 33.89 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 8.55 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.25 Bn |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | 276.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 276.88 Mn |
| Sep 30, 2025 | 139.16 Mn |
| Jun 30, 2025 | 89.14 Mn |
| Mar 31, 2025 | 103.74 Mn |
| Dec 31, 2024 | 129.52 Mn |
| Sep 30, 2024 | 161.92 Mn |
| Jun 30, 2024 | 177.35 Mn |
| Mar 31, 2024 | 215.47 Mn |
| Dec 31, 2023 | 229.18 Mn |
| Sep 30, 2023 | 274.92 Mn |
| Jun 30, 2023 | 315.41 Mn |
| Mar 31, 2023 | 350.56 Mn |
| Dec 31, 2022 | 383.17 Mn |
| Sep 30, 2022 | 424.75 Mn |
| Jun 30, 2022 | 484.61 Mn |
| Mar 31, 2022 | 556.27 Mn |
| Dec 31, 2021 | 620.09 Mn |
| Sep 30, 2021 | 686.27 Mn |
| Jun 30, 2021 | 397.99 Mn |
| Dec 31, 2020 | 117.38 Mn |